China-sourced cancer drug enters U.S. clinical trials
San Diego, CA & Research Triangle Park, N.C. – September 28, 2010 — HUYA Bioscience International (HUYA), the leader in U.S.-China pharmaceutical co-development, and Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide, today announced an agreement to co- develop a new cancer drug, HBI-8000, sourced in China by HUYA. Continue reading